Kayne Anderson Rudnick Investment Management LLC trimmed its holdings in STAAR Surgical (NASDAQ:STAA - Free Report) by 88.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,962 shares of the medical instruments supplier's stock after selling 503,040 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned 0.13% of STAAR Surgical worth $1,529,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in STAAR Surgical in the 4th quarter valued at approximately $180,000. Quantbot Technologies LP acquired a new stake in STAAR Surgical during the fourth quarter worth $278,000. Y Intercept Hong Kong Ltd bought a new stake in STAAR Surgical in the 4th quarter valued at $292,000. Counterpoint Mutual Funds LLC bought a new position in shares of STAAR Surgical during the 4th quarter worth about $298,000. Finally, HighTower Advisors LLC boosted its position in shares of STAAR Surgical by 42.6% during the 4th quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier's stock valued at $315,000 after acquiring an additional 3,871 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company's stock.
Insiders Place Their Bets
In other news, major shareholder Broadwood Partners, L.P. bought 8,200 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $15.08 per share, for a total transaction of $123,656.00. Following the completion of the acquisition, the insider now owns 13,518,591 shares in the company, valued at approximately $203,860,352.28. This represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 1,742,581 shares of company stock valued at $28,407,543 in the last quarter. 1.00% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
STAA has been the topic of several recent analyst reports. Stifel Nicolaus decreased their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, February 12th. StockNews.com lowered shares of STAAR Surgical from a "hold" rating to a "sell" rating in a report on Thursday, February 13th. Piper Sandler cut their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, February 12th. BTIG Research cut shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th. Finally, William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $24.25.
Read Our Latest Stock Report on STAA
STAAR Surgical Trading Down 0.1 %
Shares of STAAR Surgical stock traded down $0.02 during trading on Monday, reaching $18.02. The stock had a trading volume of 132,891 shares, compared to its average volume of 794,043. The company has a market capitalization of $888.59 million, a price-to-earnings ratio of -43.98 and a beta of 0.75. The stock has a fifty day moving average price of $17.22 and a two-hundred day moving average price of $22.73. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $49.86.
STAAR Surgical Company Profile
(
Free Report)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Recommended Stories
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
